Ultragenyx Pharmaceuticals’ Phase 3 program in Angelman syndrome collapsed, with apazunersen (GTX-102) failing both key endpoints in the Aspire study. The result cuts against early signals that had supported investor and patient expectations for a therapy aimed at improving cognition and broader multidomain function in a disorder with no FDA-approved treatments.